X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE GLENMARK PHARMA SUVEN LIFE/
GLENMARK PHARMA
 
P/E (TTM) x 19.2 12.2 157.0% View Chart
P/BV x 3.6 3.2 110.3% View Chart
Dividend Yield % 1.1 0.4 281.4%  

Financials

 SUVEN LIFE   GLENMARK PHARMA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
GLENMARK PHARMA
Mar-17
SUVEN LIFE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs339993 34.1%   
Low Rs144729 19.8%   
Sales per share (Unadj.) Rs39.2325.5 12.1%  
Earnings per share (Unadj.) Rs7.539.3 19.0%  
Cash flow per share (Unadj.) Rs8.848.7 18.0%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.80.2 356.7%  
Book value per share (Unadj.) Rs49.0159.2 30.8%  
Shares outstanding (eoy) m127.28282.17 45.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.22.6 232.6%   
Avg P/E ratio x32.421.9 147.7%  
P/CF ratio (eoy) x27.517.7 155.5%  
Price / Book Value ratio x4.95.4 91.1%  
Dividend payout %26.85.1 526.6%   
Avg Mkt Cap Rs m30,732242,991 12.6%   
No. of employees `0001.013.0 7.4%   
Total wages/salary Rs m41616,408 2.5%   
Avg. sales/employee Rs Th5,236.17,083.9 73.9%   
Avg. wages/employee Rs Th436.51,265.4 34.5%   
Avg. net profit/employee Rs Th995.5855.1 116.4%   
INCOME DATA
Net Sales Rs m4,99591,857 5.4%  
Other income Rs m194374 51.8%   
Total revenues Rs m5,18992,230 5.6%   
Gross profit Rs m1,23320,367 6.1%  
Depreciation Rs m1672,644 6.3%   
Interest Rs m542,373 2.3%   
Profit before tax Rs m1,20515,724 7.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m2553,827 6.7%   
Profit after tax Rs m95011,088 8.6%  
Gross profit margin %24.722.2 111.3%  
Effective tax rate %21.224.3 87.0%   
Net profit margin %19.012.1 157.5%  
BALANCE SHEET DATA
Current assets Rs m4,98668,746 7.3%   
Current liabilities Rs m1,04227,027 3.9%   
Net working cap to sales %79.045.4 173.8%  
Current ratio x4.82.5 188.1%  
Inventory Days Days6185 71.7%  
Debtors Days Days3996 41.0%  
Net fixed assets Rs m3,12624,132 13.0%   
Share capital Rs m127282 45.1%   
"Free" reserves Rs m3,71744,643 8.3%   
Net worth Rs m6,23644,925 13.9%   
Long term debt Rs m43245,363 1.0%   
Total assets Rs m8,079117,639 6.9%  
Interest coverage x23.27.6 304.6%   
Debt to equity ratio x0.11.0 6.9%  
Sales to assets ratio x0.60.8 79.2%   
Return on assets %12.411.4 108.6%  
Return on equity %15.224.7 61.7%  
Return on capital %18.919.1 98.6%  
Exports to sales %87.50-   
Imports to sales %12.20-   
Exports (fob) Rs m4,371NA-   
Imports (cif) Rs m611NA-   
Fx inflow Rs m4,66656,152 8.3%   
Fx outflow Rs m9428,084 11.7%   
Net fx Rs m3,72448,068 7.7%   
CASH FLOW
From Operations Rs m9226,574 14.0%  
From Investments Rs m-619-7,124 8.7%  
From Financial Activity Rs m-6985,432 -12.9%  
Net Cashflow Rs m-3961,992 -19.9%  

Share Holding

Indian Promoters % 63.4 48.3 131.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 6.9 -  
FIIs % 0.0 34.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.5 347.6%  
Shareholders   37,287 56,727 65.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare SUVEN LIFE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 23, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE - JUBILANT LIFE SCIENCES COMPARISON

COMPARE SUVEN LIFE WITH

MARKET STATS